Precision BioSciences (DTIL) Expected to Announce Earnings on Thursday

Precision BioSciences (NASDAQ:DTIL) will likely be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Precision BioSciences to announce earnings of ($0.71) per share and revenue of $1.40 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The business had revenue of $10.84 million for the quarter, compared to analysts’ expectations of $4.05 million. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 85.37%. On average, analysts expect Precision BioSciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Precision BioSciences Trading Down 3.9%

DTIL opened at $6.89 on Thursday. Precision BioSciences has a one year low of $3.53 and a one year high of $9.62. The company has a debt-to-equity ratio of 0.29, a current ratio of 14.02 and a quick ratio of 14.02. The business has a 50 day simple moving average of $7.36 and a two-hundred day simple moving average of $6.19. The firm has a market capitalization of $177.76 million, a price-to-earnings ratio of -1.88 and a beta of 1.25.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Weiss Ratings raised Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Oppenheimer initiated coverage on Precision BioSciences in a research note on Tuesday, June 9th. They issued an “outperform” rating and a $20.00 price target for the company. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a report on Thursday, July 9th. Finally, JonesTrading reaffirmed a “buy” rating and issued a $30.00 target price on shares of Precision BioSciences in a research report on Friday, April 17th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $32.25.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Engineers Gate Manager LP bought a new position in shares of Precision BioSciences in the fourth quarter worth approximately $43,000. Occudo Quantitative Strategies LP purchased a new position in Precision BioSciences in the 4th quarter worth approximately $52,000. Virtu Financial LLC purchased a new position in Precision BioSciences in the 3rd quarter worth approximately $84,000. Velan Capital Investment Management LP bought a new position in Precision BioSciences in the 3rd quarter valued at approximately $110,000. Finally, Citadel Advisors LLC bought a new position in Precision BioSciences in the 3rd quarter valued at approximately $122,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.